Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios

Journal of Hepatology

Volumn 62, Issue 6, 2015, Pages 1256-1264

  Wolffram, Ingmar ^a   Petroff, David ^b   Bätz, Olaf ^c   Jedrysiak, Katrin ^c   Kramer, Jan ^c   Tenckhoff, Hannelore ^d   Berg, Thomas ^d   Wiegand, Johannes ^d  

^a Südstadtpraxis Paderborn   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c LADR GmbH MVZ Dr Kramer and Kollegen   (Germany)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Efficacy; Hepatitis B; Hepatitis C; Screening strategy

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIGEN; VIRUS RNA; HEPATITIS C ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; DRUG USE; FEMALE; HEPATITIS B; HEPATITIS C; HOMOSEXUALITY; HUMAN; IMMIGRANT; IMMIGRATION; MAJOR CLINICAL STUDY; MALE; MIGRATION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRIVATE PRACTICE; QUESTIONNAIRE; RISK FACTOR; SEXUAL INTERCOURSE; VIRUS LOAD; ADOLESCENT; AGED; BLOOD; CHILD; GERMANY; MASS SCREENING; MIDDLE AGED; PRIMARY HEALTH CARE; PROCEDURES; PROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; CHILD; FEMALE; GERMANY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84929605635     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.01.011     Document Type: Article

References (27)

1. T.T. Chang, Y.F. Liaw, S.S. Wu, E. Schiff, K.H. Han, and C.L. Lai Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
2. P. Marcellin, E. Gane, M. Buti, N. Afdhal, W. Sievert, and I.M. Jacobson Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
3. W.R. Kim, N.A. Terrault, R.A. Pedersen, T.M. Therneau, E. Edwards, and A.A. Hindman Trends in waiting list registration for liver transplantation for viral hepatitis in the United States Gastroenterology 137 2009 1680 1686
4. J.J. Feld, K.V. Kowdley, E. Coakley, S. Sigal, D.R. Nelson, and D. Crawford Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
5. K.V. Kowdley, S.C. Gordon, K.R. Reddy, L. Rossaro, D.E. Bernstein, and E. Lawitz Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 20 2014 1879 1888
6. F. Poordad, C. Hezode, R. Trinh, K.V. Kowdley, S. Zeuzem, and K. Agarwal ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 21 2014 1973 1982
7. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
8. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
9. G.L. Davis, M.J. Alter, H. El-Serag, T. Poynard, and L.W. Jennings Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 521
10. D.B. Rein, J.S. Wittenborn, C.M. Weinbaum, M. Sabin, B.D. Smith, and S.B. Lesesne Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States Dig Liver Dis 43 2011 66 72
11. H. Razavi, I. Waked, C. Sarrazin, R.P. Myers, R. Idilman, and F. Calinas The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm J Viral Hepat 21 2014 34 59
12. B.D. Smith, R.L. Morgan, G.A. Beckett, Y. Falck-Ytter, D. Holtzman, and J.W. Ward Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention Ann Intern Med 157 2012 817 822
13. M.L. LeFevre Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. preventive services task force recommendation statement Ann Intern Med 161 1 2014 58 66
14. M. Cornberg, U. Protzer, J. Petersen, H. Wedemeyer, T. Berg, and W. Jilg Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline Z Gastroenterol 49 2011 871 930
15. C. Sarrazin, T. Berg, R.S. Ross, P. Schirmacher, H. Wedemeyer, and U. Neumann Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection Z Gastroenterol 48 2010 289 351
16. Statistisches Bundesamt. Bevölkerung und Erwerbstätigkeit. Vorläufige Ergebnisse der Bevölkerungsfortschreibung auf Grundlage des Zensus 2011. Wiesbaden; 2014. Report No.: 5124103119004.
17. Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland. Mitteilungen des Zentralinstituts für die kassenärztliche Versorgung. Berlin; 2012.
18. Statistisches Bundesamt. Bevölkerung und Erwerbstätigkeit. Bevölkerung mit Migrationshintergrund. Ergebnisse des Mikrozensus 2013; 2014.
19. C. Poethko-Muller, R. Zimmermann, O. Hamouda, M. Faber, K. Stark, and R.S. Ross Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1) Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56 2013 707 715
20. H. Wedemeyer, A.S. Duberg, M. Buti, W.M. Rosenberg, S. Frankova, and G. Esmat Strategies to manage hepatitis C virus (HCV) disease burden J Viral Hepat 21 2014 60 89
21. L. Lavin, B. Faliu, Z. Bessa, and D. Houssin National control plan for hepatitis B and C, 2009-2012: public health issues Rev Prat 61 2011 8 9
22. G.V. Papatheodoridis, E. Tsochatzis, S. Hardtke, and H. Wedemeyer Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review Liver Int 34 10 2014 1452 1463
23. H. Wedemeyer, W.P. Hofmann, S. Lueth, P. Malinski, R. Thimme, and F. Tacke ALT screening for chronic liver diseases: scrutinizing the evidence Z Gastroenterol 48 2010 46 55
24. M. Kabiri, A.B. Jazwinski, M.S. Roberts, A.J. Schaefer, and J. Chhatwal The changing burden of hepatitis C virus infection in the United States: model-based predictions Ann Intern Med 161 2014 170 180
25. E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi Global epidemiology and genotype distribution of the hepatitis C virus infection J Hepatol 61 2014 S45 S57
26. K. Carney, S. Dhalla, A. Aytaman, C.T. Tenner, and F. Francois Association of tattooing and hepatitis C virus infection: a multicenter case-control study Hepatology 57 2013 2117 2123
27. B.D. Smith, R.L. Morgan, G.A. Beckett, Y. Falck-Ytter, D. Holtzman, and C.G. Teo Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965 MMWR Recomm Rep 61 2012 1 32